Isolation of tumor-resident CD8+ T cells from human lung tumors

STAR Protoc. 2021 Jan 12;2(1):100267. doi: 10.1016/j.xpro.2020.100267. eCollection 2021 Mar 19.


CD103+CD8+ tumor-resident memory T cells (TRM) are important components of anti-tumor immunity. However, their role in response to cancer immunotherapy is not fully understood. The protocol describes how to isolate CD8+ T cells and autologous tumor cells from human lung tumors to study the functional activities of CD8+ T cells. Tumors are heterogeneous in terms of the quantity and quality of immune cell types, so the yield of TRM cells depends on the features of the tumor. For complete details on the use and execution of this protocol, please refer to Corgnac et al. (2020).

Keywords: Cancer; Cell isolation; Flow cytometry/mass cytometry; Immunology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes / immunology*
  • Cell Separation*
  • Humans
  • Lung Neoplasms / immunology*
  • Lymphocytes, Tumor-Infiltrating / immunology*
  • Memory T Cells / immunology*
  • Tumor Microenvironment / immunology*